Business Description
Verastem Inc
NAICS : 325412
SIC : 2834
ISIN : US92337C1045
Description
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.73 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 1.29 | |||||
| Debt-to-EBITDA | -0.47 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -10.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 1.5 | |||||
| 3-Year EPS without NRI Growth Rate | 8.6 | |||||
| 3-Year FCF Growth Rate | -14.3 | |||||
| 3-Year Book Growth Rate | -34.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 22.94 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.62 | |||||
| 9-Day RSI | 41.76 | |||||
| 14-Day RSI | 48.83 | |||||
| 3-1 Month Momentum % | 59.84 | |||||
| 6-1 Month Momentum % | 21.88 | |||||
| 12-1 Month Momentum % | -39.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.23 | |||||
| Quick Ratio | 3.23 | |||||
| Cash Ratio | 3.03 | |||||
| Days Sales Outstanding | 126.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.2 | |||||
| Shareholder Yield % | -1.57 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1145.05 | |||||
| Net Margin % | -934.54 | |||||
| FCF Margin % | -1080.05 | |||||
| ROE % | -166.79 | |||||
| ROA % | -68.56 | |||||
| ROIC % | -856.34 | |||||
| 3-Year ROIIC % | 1120.84 | |||||
| ROC (Joel Greenblatt) % | -8626.12 | |||||
| ROCE % | -82.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.1 | |||||
| PB Ratio | 16.36 | |||||
| Price-to-Tangible-Book | 14.93 | |||||
| EV-to-EBIT | -1.68 | |||||
| EV-to-Forward-EBIT | -1.71 | |||||
| EV-to-EBITDA | -1.68 | |||||
| EV-to-Revenue | 14.93 | |||||
| EV-to-Forward-Revenue | 27.58 | |||||
| EV-to-FCF | -1.37 | |||||
| Price-to-Net-Current-Asset-Value | 32.15 | |||||
| Price-to-Net-Cash | 8.89 | |||||
| Earnings Yield (Greenblatt) % | -59.69 | |||||
| FCF Yield % | -54.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verastem Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9.29 | ||
| EPS (TTM) (€) | -2.933 | ||
| Beta | -1.21 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.57 | ||
| Volatility % | 102.5 | ||
| 14-Day RSI | 48.83 | ||
| 14-Day ATR (€) | 0.301053 | ||
| 20-Day SMA (€) | 4.3515 | ||
| 12-1 Month Momentum % | -39.53 | ||
| 52-Week Range (€) | 1.9 - 12.5 | ||
| Shares Outstanding (Mil) | 44.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verastem Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verastem Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Verastem Inc Frequently Asked Questions
What is Verastem Inc(FRA:2VSA)'s stock price today?
The current price of FRA:2VSA is €4.18. The 52 week high of FRA:2VSA is €12.50 and 52 week low is €1.90.
When is next earnings date of Verastem Inc(FRA:2VSA)?
The next earnings date of Verastem Inc(FRA:2VSA) is 2025-03-14 Est..
Does Verastem Inc(FRA:2VSA) pay dividends? If so, how much?
Verastem Inc(FRA:2VSA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers